NO20060612L - Spiro [1-azabicyklo[2.2.2]-oktan-3,5'-oksazolidin]-2'-on-derivater med affinitet til alfa-7-nikotin-acetylcholin reseptoren - Google Patents

Spiro [1-azabicyklo[2.2.2]-oktan-3,5'-oksazolidin]-2'-on-derivater med affinitet til alfa-7-nikotin-acetylcholin reseptoren

Info

Publication number
NO20060612L
NO20060612L NO20060612A NO20060612A NO20060612L NO 20060612 L NO20060612 L NO 20060612L NO 20060612 A NO20060612 A NO 20060612A NO 20060612 A NO20060612 A NO 20060612A NO 20060612 L NO20060612 L NO 20060612L
Authority
NO
Norway
Prior art keywords
compounds
oxazolidin
azabicyclo
spiro
octane
Prior art date
Application number
NO20060612A
Other languages
English (en)
Norwegian (no)
Inventor
Eifion Phillips
Hui-Fang Chang
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20060612L publication Critical patent/NO20060612L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20060612A 2003-07-08 2006-02-08 Spiro [1-azabicyklo[2.2.2]-oktan-3,5'-oksazolidin]-2'-on-derivater med affinitet til alfa-7-nikotin-acetylcholin reseptoren NO20060612L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48552303P 2003-07-08 2003-07-08
PCT/GB2004/002904 WO2005005435A1 (en) 2003-07-08 2004-07-06 Spiro ′1-azabicyclo ′2.2.2!octan-3,5′-oxazolidin -2′-one! derivatives with affinity to the alpha7 nicotinic acetylcholine receptor

Publications (1)

Publication Number Publication Date
NO20060612L true NO20060612L (no) 2006-04-06

Family

ID=34062082

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060612A NO20060612L (no) 2003-07-08 2006-02-08 Spiro [1-azabicyklo[2.2.2]-oktan-3,5'-oksazolidin]-2'-on-derivater med affinitet til alfa-7-nikotin-acetylcholin reseptoren

Country Status (17)

Country Link
US (1) US7514567B2 (enExample)
EP (1) EP1654264A1 (enExample)
JP (1) JP2007516200A (enExample)
KR (1) KR20060057569A (enExample)
CN (1) CN1829721A (enExample)
AR (1) AR045040A1 (enExample)
AU (1) AU2004255920B2 (enExample)
BR (1) BRPI0412382A (enExample)
CA (1) CA2531510A1 (enExample)
IL (1) IL172762A0 (enExample)
MX (1) MXPA06000231A (enExample)
NO (1) NO20060612L (enExample)
NZ (1) NZ545132A (enExample)
SA (1) SA04250212B1 (enExample)
TW (1) TW200524942A (enExample)
WO (1) WO2005005435A1 (enExample)
ZA (1) ZA200600154B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008524208A (ja) * 2004-12-15 2008-07-10 アストラゼネカ・アクチエボラーグ ニコチン性アセチルコリン受容体リガンド
US7618989B2 (en) 2006-08-15 2009-11-17 Wyeth Tricyclic oxazolidone derivatives useful as PR modulators
WO2008021337A1 (en) * 2006-08-15 2008-02-21 Wyeth Oxazinan-2-one derivatives useful as pr modulators
US7649007B2 (en) 2006-08-15 2010-01-19 Wyeth Llc Oxazolidine derivatives as PR modulators
WO2008021309A1 (en) 2006-08-15 2008-02-21 Wyeth Imidazolidin-2-one derivatives useful as pr modulators
TW200815428A (en) 2006-08-15 2008-04-01 Wyeth Corp Oxazolidone derivatives as PR modulators
JP2010505844A (ja) * 2006-10-03 2010-02-25 ガレオン・フアーマシユーチカルズ・インコーポレーテツド S−ニトロソチオール化合物および関連誘導体
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
US7863291B2 (en) 2008-04-23 2011-01-04 Bristol-Myers Squibb Company Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
US8309577B2 (en) 2008-04-23 2012-11-13 Bristol-Myers Squibb Company Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands
CA2730844A1 (en) * 2008-07-17 2010-01-21 Thomas Bretschneider Heterocyclic compounds used as pesticides
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
UA107791C2 (en) * 2009-05-05 2015-02-25 Dow Agrosciences Llc Pesticidal compositions
EP2470516A1 (en) * 2009-08-27 2012-07-04 Yeda Research and Development Co. Ltd. Oligo- and polyfurans, preparation and uses thereof
US8507516B2 (en) 2009-10-28 2013-08-13 Bristol-Myers Squibb Company Azabicyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands
US8278320B2 (en) 2009-10-28 2012-10-02 Bristol-Myers Squibb Company Azabicyclo[2.2.1]heptane compounds as alpha-7 nicotinic acetylcholine receptor ligands
CN103119034B (zh) * 2010-04-16 2016-08-03 拜耳知识产权有限责任公司 作为害虫防治剂的杂环化合物
CN103025744A (zh) 2010-04-30 2013-04-03 百时美施贵宝公司 作为α-7烟碱乙酰胆碱受体配体前药的氮杂二环胺N-氧化物化合物
EA201300160A1 (ru) 2010-07-22 2013-06-28 Новартис Аг 2,3,5-тризамещенные тиофены и их применение
BR112013009823A2 (pt) 2010-10-22 2016-07-05 Bayer Ip Gmbh novos compostos heterocíclicos como pesticidas
CN104302640A (zh) 2012-03-16 2015-01-21 埃克希金医药品有限公司 3,5-二氨基吡唑激酶抑制剂
US20150284380A1 (en) 2012-10-31 2015-10-08 Bayer Cropscience Ag Novel heterocyclic compounds as pest control agents
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
MY191736A (en) 2014-12-23 2022-07-13 Axikin Pharmaceuticals Inc 3,5-diaminopyrazole kinase inhibitors
KR102218333B1 (ko) 2016-06-07 2021-02-22 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
SG11201908820VA (en) 2017-03-23 2019-10-30 Jacobio Pharmaceuticals Co Ltd Novel heterocyclic derivatives useful as shp2 inhibitors
CN112839935A (zh) 2018-09-26 2021-05-25 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4855290A (en) * 1985-05-10 1989-08-08 State Of Israel, Represented By Prime Minister's Office, Israel Institute For Biological Research Derivatives of quinuclidine
JP3708962B2 (ja) * 1994-08-24 2005-10-19 アストラゼネカ・アクチエボラーグ 治療に有用なスピロ−アザ二環式化合物
AU2001241056A1 (en) 2000-03-09 2001-09-17 Mitsubishi Pharma Corporation Spiro compounds, process for preparing the same and use thereof as drugs

Also Published As

Publication number Publication date
AU2004255920A1 (en) 2005-01-20
US20060154945A1 (en) 2006-07-13
TW200524942A (en) 2005-08-01
MXPA06000231A (es) 2006-04-11
ZA200600154B (en) 2007-04-25
BRPI0412382A (pt) 2006-09-19
WO2005005435A1 (en) 2005-01-20
EP1654264A1 (en) 2006-05-10
US7514567B2 (en) 2009-04-07
SA04250212B1 (ar) 2009-08-11
CN1829721A (zh) 2006-09-06
KR20060057569A (ko) 2006-05-26
JP2007516200A (ja) 2007-06-21
IL172762A0 (en) 2006-04-10
NZ545132A (en) 2009-07-31
CA2531510A1 (en) 2005-01-20
AU2004255920B2 (en) 2008-05-15
AR045040A1 (es) 2005-10-12

Similar Documents

Publication Publication Date Title
MXPA06000231A (es) Derivados espiro '1-azabiciclo'2.2.2!octan-3,5'-oxazolidin-2'-ona! con afinidad a la alfa7 del receptor nicotinico para acetilcolina.
NO20061657L (no) Pyrolderivater med antibakteriell aktivitet
NO20060981L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
NO20055092L (no) Substituerte pyrimidioner
BR0115999A (pt) Composto, composição farmacêutica que compreende o mesmo, sua utilização, processo para o tratamento profilático ou terapêutico de diabetes do tipo ii e processo para a preparação do composto
ATE370138T1 (de) Neue imidazopyridine und ihre verwendung
WO2007040438A3 (en) Novel imidazo [4,5 -b] pyridine derivatives as inhibitors of glycogen synthase kinase 3 for use in the treatment of dementia and neurodegenerative disorders
NO20072089L (no) Benzimidazolderivater, sammensetninger som inneholder dem, fremstilling derav og anvendelse derav
BRPI0412343A (pt) derivados de piridazina e seu uso como agentes terapêuticos
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
BRPI0606817A2 (pt) derivados de piridazina e seu uso como agentes terapêuticos
NO20055892L (no) Karboksylsyrederivater
WO2003048164A3 (en) Adenosine a2a receptor antagonists
NO20062691L (no) Azabicykliske heterocykler som cannabinoide reseptormodulatorer
NO20052130L (no) Sterk inhibitor for HCV-serin-protease
NO20085271L (no) Muscarin reseptoragonister som er effektive i behandling av smerte, Alzheimers sykdom og schizofreni
BRPI0407253A (pt) Heterociclil-3-sulfonilindazóis como ligandos 5-hidroxitriptamina-6 processo de preparação dos mesmos, seus usos na preparação de uma composição farmacêutica e composição farmacêutica compreendendo os referidos compostos
NO990433L (no) Nye forbindelser og blandinger for behandling av sykdommer i forbindelse med tryptase-aktivitet
BR9807950A (pt) Composto, composição farmacêutica, uso de um composto, e, processos para tratar ou reduzir o risco de doenças ou condições humanas, o risco de doença inflamatória o risco da dor e para a preparação de um composto
NO20061839L (no) Benzimidazolderivater, sammensetninger inneholdende dem, fremstilling derav, og anvendelse derav
NO20055766L (no) Positive modulatorer av nikotinacetylcholinreseptorer
NO20060147L (no) Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav
MX344556B (es) Agonista de subtipo de receptor 5-ht1a.
NO20064010L (no) Indazolderivater og farmasoytiske preparater inneholdelse slike
BRPI0409882A (pt) compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application